Date: 2011-05-20
Type of information: Fundraising
Company: ACS Biomarker (The Netherlands)
Investors: Life Sciences Fund Amsterdam (The Netherlands)
Limburg Ventures (The Netherlands)
Amount: undisclosed
Funding type: financing round
Planned used: The funding will be used to further develop the product pipeline and discover novel biomarkers that improve diagnosis, prognosis and management of cardiac diseases.
Others: ACS Biomarker, a Dutch biotechnology company focused on the discovery, validation and commercialization of novel cardiovascular biomarkers announced the closing of a financing round. The investment is made by the Life Sciences Fund Amsterdam and Limburg Ventures. The founders of ACS Biomarker, prof. dr. Yigal Pinto, prof. dr. Tilman Hackeng, and prof. dr. Mat Daemen have built a track-record in cardiovascular biomarker discovery. Their research enabled ACS Biomarker to successfully out-license its first protein marker Galectin-3 to BG Medicine, Inc. The Galectin-3 in-vitro diagnostic immune-assay was recently approved by the FDA and is now available in the clinic.ACS Biomarker established a close collaboration with two renowned cardiovascular research institutes, the Heart Failure Research Center of the AMC Amsterdam and CARIM of UMC Maastricht. Both institutes out-licensed their intellectual property rights originating from protein and miRNA based cardiovascular biomarker research exclusively to ACS Biomarker. Following the financing, ACS Biomarker appointed a new CEO, Heico Breek. He will lead the company’s operations from the offices in Amsterdam and Maastricht.
Therapeutic area: Cardiovascular diseases
